Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19
Female Sexual Function During the COVID-19 Pandemic in the United States
Hriday P. Bhambhvani, BS,1 Tony Chen, MD,1 Alex M. Kasman, MD,1 Genester Wilson-King, MD,2 Ekene Enemchukwu, MD, MPH,1 and Michael L. Eisenberg, MD1

ABSTRACT

Introduction: International studies have demonstrated increasing rates of sexual dysfunction amidst the coronavirus disease 2019 (COVID-19) pandemic; however, the impact of the pandemic on female sexual function in the United States is unknown.

Aim: To assess the impact of the COVID-19 pandemic on female sexual function and frequency in the United States.

Methods: A pre-pandemic survey containing the Female Sexual Function Index (FSFI) and demographic questions was completed by adult women in the United States from October 20, 2019 and March 1, 2020. The same women were sent a follow-up survey also containing the FSFI, as well as the Patient Health Questionnaire for Depression and Anxiety with 4 items (PHQ-4), and questions pertaining to mask wearing habits, job loss, and relationship changes. Risk for female sexual dysfunction (RFSD) was defined as FSFI < 26.55.

Main Outcome Measure: Differences in pre-pandemic and intra-pandemic female sexual function, measured by the FSFI, and sexual frequency.

Results: Ninety-one women were included in this study. Overall FSFI significantly decreased during the pandemic (27.2 vs 28.8, P = .002), with domain-specific decreases in arousal (4.41 vs 4.86, P = .0002), lubrication (4.90 vs 5.22, P = .004), and satisfaction (4.40 vs 4.70, P = .04). There was no change in sexual frequency. Contingency table analysis of RFSD prior to and during the pandemic revealed significantly increased RFSD during the pandemic (P = .002). Women who developed RFSD during the pandemic had higher PHQ-4 anxiety subscale scores (3.74 vs 2.53, P = .01) and depression subscale scores (2.74 vs 1.43, P = .001) than those who did not. Development of FSD was not associated with age, home region, relationship status, mask wearing habits, knowing someone who tested positive for COVID-19, relationship change, or job loss and/or reduction during the pandemic.

Conclusion: In this population of female cannabis users, risk for sexual dysfunction increased amidst the COVID-19 pandemic and is associated with depression and anxiety symptoms. Bhambhvani HP, Chen T, Wilson-King AM, et al. Female Sexual Function During the COVID-19 Pandemic in the United States. Sex Med 2021;9:100355.

Copyright © 2021, International Society of Sexual Medicine. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Key Words: Sex; orgasm, Intimacy; Pain; Frequency; Intercourse

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) has led to a global pandemic which has disrupted lives and health care delivery systems across the world. Ever since the first shelter-in-place orders were first enacted in the United States in March 2020 in an effort to limit the spread of the virus, the social distancing protocols and shutdowns of bars, restaurants, schools, and other public-gatherings have caused significant disruption. Social normalcy has been
upended and many aspects of people’s lives have been drastically altered including economic, social, political, as well as within the realms of individual private, intimate lives. Unemployment has risen, and with it, loss of work-related healthcare insurance; mental health impacts of increased isolation combined with economic uncertainty has worsened depression and anxiety. Early reports show signs of the pandemic’s downstream effects impacting women differently than men: women are typically leaned on more for childcare, a need that’s magnified with children learning remotely. Potentially as a result of the increased need for childcare and home schooling, recent reports suggest women are at higher risk of pandemic-related unemployment.

Sexual health requires a state of well-being from women’s physical, emotional, social, and mental domains. Sexual dysfunction can arise from stresses and disruptions in any of the interrelated psychological, biological, or social domains responsible for sexual health including many of which may be caused by the global pandemic. Indeed, a recent study of clinical sexologists and their patients’ sexual health during the pandemic highlighted the role of mental health issues as precursors of sexual difficulties.

Early surveys have sought to characterize the impacts of the pandemic on female sexual behavior. They have described large proportions of female participants reporting negative impacts on Female Sexual Function Index (FSFI) scores. They have drawn links between stress and loneliness experienced during the pandemic to negative evaluations of one’s own sex life and they have reported lower overall levels of sexual activity. However, these studies rely heavily on survey respondent recall regarding pre-pandemic function, which risks recall bias. Furthermore, a majority of these studies have been completed outside of the United States, and may not be generalizable to those living in the U.S. as every country has shown a unique medical and psychological response to the pandemic.

Our research group has been prospectively collecting sexual function data on a sexually active longitudinal patient cohort. A baseline survey was completed in November and/or December 2019 before the COVID-19 spread, which makes this a unique pre-Covid-19 dataset available for comparison. Timing of follow-up survey dissemination coincided with post-pandemic shelter-in-place, allowing for pre-pandemic and intra-pandemic analysis. The aim of the present study is to answer the question, “Is the COVID-19 pandemic associated with a decrease in female sexual function in the United States?” We hypothesized the pandemic would be associated with increased risk for female sexual dysfunction.

METHODS

Study Population

We leveraged a convenience sample of women surveyed for a separate study of sexual function which began enrollment immediately prior to the onset of the COVID-19 pandemic, between October 20, 2019 and March 1, 2020 that comprised our pre-COVID dataset. These were women who visited a partner cannabis dispensary and were invited to complete an uncompensated, anonymous online survey on the Qualtrics (Provo, UT) platform. The same group of women were then invited to complete a follow-up survey during the pandemic between August 1, 2020 and October 10, 2020 within the nationwide social distancing protocol time periods, comprising the intra-pandemic dataset. Prior to beginning the survey, each participant was given a form pertaining to informed consent, and completion of the survey implied informed consent to participate in the study. Sexually inactive participants were excluded from analyses regarding sexual function due to established limitations of the FSFI in quantifying the sexual function of sexually inactive women. This study was approved by the Institutional Review Board at the Stanford University School of Medicine.

Survey Instruments

All participants were administered the same pre-pandemic and intra-pandemic surveys. The pre-pandemic survey has been described in detail previously and includes questions on demographic information and past medical history, as well as the FSFI. The FSFI is a validated questionnaire consisting of 19 questions, each scored on a Likert scale from 0/1 to 5, for a maximum total score of 36 with the following 6 domains, each worth 6 points: desire, arousal, lubrication, orgasm, satisfaction, and pain. The presence of risk for female sexual dysfunction (RFSD) was defined as an overall FSFI score less than 26.55, as previously described. The pandemic survey consisted of the FSFI as well as questions regarding sexual frequency, mask wearing habits, job loss during the pandemic, whether participants knew someone who tested positive, changes in relationship during the pandemic, and anxiety and/or depression symptoms during the pandemic. Anxiety and depression symptoms were evaluated using the validated Patient Health Questionnaire for Depression and Anxiety with 4 items (PHQ-4). The PHQ-4 is a validated screening tool for anxiety and depression consisting of two depression screening questions (PHQ-2) and two generalized anxiety disorder screening questions (GAD-2). Each question is scored on a Likert scale ranging from 0 to 3, for a total of 6 possible points for each subscore, and scores ≥ 3 for were considered anxiety or depression for their respective scales, as previously described. The specific wording and possible answers to survey questions pertaining to the pandemic are detailed in Supplemental Table 1.

Statistical Analysis

Participant characteristics were analyzed using descriptive statistics, including proportions, median, and mean ± standard deviations. Group differences in categorical variables were assessed by the χ2 test or Fisher’s exact test as appropriate. Normally distributed continuous variables were analyzed by Student’s t-test, while skewed continuous variables were analyzed by the Wilcoxon rank-sum test. The internal consistency (“reliability”) of the FSFI domains was assessed using Cronbach’s alpha (Supplemental Table 2), and all values of Cronbach’s alpha were at least 0.80, indicating good reliability. Pre-pandemic and intra-
pandemic measures of FSFI were analyzed using paired t-tests. Pre-pandemic and intra-pandemic measures of RFSD were compared using contingency table analysis with McNemar’s test for paired categorical data. Pre-pandemic and intra-pandemic measures of sexual frequency were analyzed using the Wilcoxon signed-rank test for ordered categorical data.21

All data were analyzed using R v3.5.3 (R Foundation for Statistical Computing, Vienna, Austria). The significance level for all statistical tests was set at 0.05, and all tests were two-sided.

RESULTS

A total of 91 women were included in this study. Participant characteristics are summarized in Table 1. Mean participant age ± standard deviation was 43.1 ± 11.8 years. Most women were married or in a relationship (n = 75, 82.4%), had normal BMI (n = 49, 55.7%), and had not visited their primary care provider in the last three months (n = 49, 53.8%). Approximately half of the cohort knew someone who tested positive for COVID-19 (n = 45, 49.5%) and had experienced job loss or reduction during the pandemic (n = 46, 50.5%). Most participants reported always wearing a face mask (n = 61, 67.0%) and no change in relationship status during the pandemic (n = 75, 82.4%). During the pandemic, 42 women (46.2%) screened positive for anxiety, and the average anxiety subscale score was 2.79 (range, 0-6). 22 women (24.2%) screened positive for depression, and the average depression subscale score was 1.77 (range, 0-6).

Paired analyses of sexual function and frequency before and during the pandemic are provided in Table 2. Overall FSFI was significantly decreased during the pandemic (27.2 vs 28.8, $P = .002$). Intra-pandemic decreases in FSFI were additionally noted for the arousal domain (4.41 vs 4.86, $P = .0002$), lubrication domain (4.90 vs 5.22, $P = .004$), and satisfaction domain (4.40 vs 4.70, $P = .04$). Subgroup analysis of FSFI among participants who did not experience job loss revealed decreases in intra-pandemic FSFI domains for arousal (4.83 vs 4.39, $P = .03$), lubrication (5.33 vs 4.94, $P = .045$), orgasm (5.03 vs 4.63, $P = .048$), with a trend toward decreased overall FSFI (29.00 vs 27.42, $P = .057$). Among the 58 women with known sexual frequency, there was no change in sexual frequency following the onset of the pandemic ($P = .81$). Contingency table analysis of RFSD prior to and during the pandemic revealed significantly increased RFSD during the pandemic (Table 3, $P = .002$).

Among participants who did not have RFSD prior to the pandemic, a comparison between those who remained without RFSD vs those who developed RFSD is provided in Table 4. Notably, women who developed RFSD had higher anxiety subscale scores (3.74 vs 2.53, $P = .01$) and depression subscale scores (2.74 vs 1.43, $P = .001$). Development of RFSD was not associated with age, home region, relationship status, mask wearing habits, knowing someone who tested positive for COVID-19, relationship change, or job loss and/or reduction during the pandemic.

### Table 1. Baseline characteristics of participants

| Characteristic | N (%) |
|---------------|-------|
| Total         | 91 (100%) |
| Age (mean (SD)) | 43.1 (11.8) |
| Age           |       |
| <30           | 11 (12.1) |
| 30 - 39       | 27 (29.7) |
| 40 - 49       | 24 (26.4) |
| 50 - 59       | 22 (24.2) |
| 60+           | 7 (7.7)   |
| Region        |       |
| West          | 32 (35.2) |
| International | 16 (17.6) |
| Midwest       | 9 (9.9)   |
| Northeast     | 20 (22.0) |
| South         | 14 (15.4) |
| Relationship status |       |
| Married/In a relationship | 75 (82.4) |
| Single        | 14 (15.4) |
| Unknown       | 2 (2.2)   |
| Weight (mean (SD)) | 158.0 (34.6) |
| Height (mean (SD)) | 67.4 (5.8) |
| BMI           |       |
| Normal        | 49 (55.7) |
| Underweight   | 2 (2.3)   |
| Overweight    | 20 (22.7) |
| Obese         | 12 (13.6) |
| Extremely Obese | 5 (5.5)   |
| PCP Visits in last 3 months |       |
| 0             | 49 (53.8) |
| 1             | 29 (31.9) |
| 2+            | 13 (14.3) |
| Know someone who tested positive |       |
| No            | 46 (50.5) |
| Yes           | 45 (49.5) |
| Experienced Job Loss or Reduction |       |
| No            | 45 (49.5) |
| Yes           | 46 (50.5) |
| Mask-wearing frequency |       |
| Always        | 61 (67.0) |
| Often         | 17 (18.7) |
| Sometimes     | 10 (11.0) |
| Rarely        | 1 (1.1)   |
| Never         | 2 (2.2)   |
| Relationship changed during the pandemic |       |
| No            | 75 (82.4) |
| Yes           | 16 (17.6) |
| PHQ-4 Anxiety |       |
| No            | 49 (53.8) |
| Yes           | 42 (46.2) |
| PHQ-4 Anxiety Score (mean (SD)) | 2.79 (1.80) |
| PHQ-4 Depression |       |
| No            | 69 (75.8) |
| Yes           | 22 (24.2) |
| PHQ-4 Depression Score (mean (SD)) | 1.77 (1.48) |
and Turkey have demonstrated an increase in FSD and decrease in sexual frequency among women amidst the COVID-19 pandemic in the United States. Utilizing pre-pandemic survey data as a comparison, we report an increase in female sexual dysfunction as determined by the FSFI, with no change in sexual frequency. Development of risk for female sexual dysfunction was associated with higher intra-pandemic anxiety and depression scores. There was no association between sexual function and mask wearing habits, knowing someone who tested positive, relationship status, or job loss and/or reduction during the pandemic.

Public health safety measures, ranging from physical distancing to stay-at-home orders, have been invoked across the world and are necessary to slow the spread of SARS-CoV-2. Simultaneously, however, these inherently isolating preventative measures have been linked to increased rates of depression and anxiety.22 Indeed, Ettman et al. estimated a three-fold increase in the prevalence of depression symptoms in the United States.33 Depression, anxiety, and stress are well-established risk factors for sexual dysfunction, and it follows that rates of sexual dysfunction may be increasing given a more distressed populace. To this end, some international studies have explored changes in sexual behavior and function during the pandemic with variable findings. Observational studies of women in Italy and Turkey have demonstrated an increase in FSD and decrease in frequency of intercourse with the onset of the pandemic.24,25

In a recent survey of married couples in Egypt, both men and women experienced lower sexual satisfaction during the pandemic, but women were more affected than men, likely due to relatively more anxiety and depression.26 Another survey of over 1,500 adults in Italy found that most participants (71.3%) did not report any change in their sexual desire during the pandemic.27 Likewise, a cross-sectional survey conducted in Bangladesh, India, and Nepal revealed that most (55%) participants did not believe pandemic lockdowns had affected their sexual life.28 Given the variable nature of the pandemic in each country with regard to both infection rate and policy-level interventions, these results may not be generalizable to the United States. Accordingly, our study is an important step toward understanding the effects of the pandemic on female sexual function in the United States.

Though we report statistically significant decreases in overall FSFI score, the absolute decreases are relatively modest and therefore their clinical significance may be questioned. For example, the average decrease in the overall FSFI score during the pandemic was 1.6 points. In order to assess to clinically meaningful differences in sexual function, we used the previously validated FSFI cut-point of 26.55 to define RFSD and conducted contingency table analysis, demonstrating increased RFSD during the pandemic. Additionally, the average FSFI score of our study population is somewhat higher than the average FSFI score of other, larger studies.18,29 As such, our sample may be more protected from the development of RFSD because of a higher baseline sexual function, and our findings may therefore somewhat underestimate the deleterious association of the COVID-19 pandemic with female sexual function.

The direct relationship between female sexual dysfunction and depression, anxiety, and stress has been studied extensively. Many pharmacologic therapies for depression and anxiety have FSD as a potential adverse effect, but depression and anxiety are themselves, even in the absence of treatment, risk factors for FSD. One study of antidepressant-naïve patients with major depressive disorder revealed 90% of patients had FSD per the FSFI.30 Similarly, a study of patients with generalized anxiety disorder receiving placebo treatment found that 46% of women had sexual dysfunction.31 Consistent with these results, our study finds that women who developed RFSD during the pandemic had increased depression and anxiety symptoms than women who remained without RFSD. As such, providers who encounter women presenting with sexual dysfunction should be vigilant for depression, anxiety, and stress.

### Table 2. Comparisons of sexual frequency and function before and within the pandemic

| Characteristic | Pre-pandemic | Intra-pandemic | P value |
|---------------|--------------|---------------|---------|
| DESIRE DOMAIN | 3.78 (1.19)  | 3.58 (1.12)  | 0.08    |
| Arousal Domain| 4.86 (1.22)  | 4.41 (1.25)  | 0.0002  |
| Lubrication   | 5.22 (1.18)  | 4.90 (1.35)  | 0.004   |
| Orgasm       | 4.98 (1.39)  | 4.76 (1.41)  | 0.10    |
| Satisfaction | 4.70 (1.35)  | 4.40 (1.35)  | 0.04    |
| Pain Domain  | 5.28 (1.14)  | 5.17 (1.10)  | 0.25    |
| Overall Score| 28.82 (5.67) | 27.22 (5.63) | 0.002   |

Differences in FSFI assessed using paired t-tests. The significance level was set at 0.05.

### Table 3. Contingency table analysis of female sexual dysfunction prior to and during the pandemic

|              | Intra-pandemic FSD present | Intra-pandemic FSD absent | Total | P value |
|--------------|----------------------------|---------------------------|-------|---------|
| Pre-Pandemic FSD present | 17 (81%)                 | 4 (19%)                   | 21    | 0.002   |
| Pre-Pandemic FSD absent   | 19 (27%)                 | 51 (73%)                  | 70    |         |
| Total                   | 36                        | 55                        | 91    |         |

Analysis conducted with McNemar’s test for paired categorical data. The significance level was 0.05. Row percentages listed in parentheses.
| Characteristic                                | Remained without FSD | Developed FSD | P value |
|----------------------------------------------|----------------------|---------------|---------|
| N                                            | 51                   | 19            |         |
| Age (mean (SD))                              | 42.86 (12.64)        | 44.32 (11.37) | 0.66    |
| Region                                       |                      |               |         |
| West                                         | 16 (31.4)            | 9 (47.4)      | 0.79    |
| International                                | 11 (21.6)            | 3 (15.8)      |         |
| Midwest                                      | 5 (9.8)              | 2 (10.5)      |         |
| Northeast                                    | 11 (21.6)            | 3 (15.8)      |         |
| South                                        | 8 (15.7)             | 2 (10.5)      |         |
| Relationship status                          |                      |               | 0.71    |
| Married/Relationship                         | 41 (80.4)            | 14 (73.7)     |         |
| Single                                       | 9 (17.6)             | 4 (21.1)      |         |
| Unknown                                      | 1 (2.0)              | 1 (5.3)       |         |
| Weight (mean (SD))                           | 154.39 (30.56)       | 165.26 (38.90)| 0.22    |
| Height (mean (SD))                           | 166.55 (5.05)        | 168.84 (5.70) | 0.11    |
| BMI                                          |                      |               | 0.06    |
| Normal                                       | 30 (61.2)            | 6 (31.6)      |         |
| Underweight                                  | 0 (0.0)              | 2 (10.5)      |         |
| Overweight                                   | 10 (20.4)            | 7 (36.8)      |         |
| Obese                                        | 7 (14.3)             | 3 (15.8)      |         |
| Extremely Obese                              | 2 (4.1)              | 1 (5.3)       |         |
| PCP Visits in last 3 months                  |                      |               | 0.37    |
| 0                                            | 31 (60.8)            | 8 (42.1)      |         |
| 1                                            | 14 (27.5)            | 8 (42.1)      |         |
| 2+                                           | 6 (11.8)             | 3 (15.8)      |         |
| Know someone who tested positive             |                      |               | 0.59    |
| No                                           | 27 (52.9)            | 8 (42.1)      |         |
| Yes                                          | 24 (47.1)            | 11 (57.9)     |         |
| Experienced Job Loss or Reduction            |                      |               | 1.00    |
| No                                           | 26 (51.0)            | 10 (52.6)     |         |
| Yes                                          | 25 (49.0)            | 9 (47.4)      |         |
| Mask-wearing frequency                       |                      |               | 0.79    |
| Always                                       | 34 (66.7)            | 15 (78.9)     |         |
| Often                                        | 10 (19.6)            | 2 (10.5)      |         |
| Sometimes                                    | 5 (9.8)              | 2 (10.5)      |         |
| Rarely                                       | 1 (2.0)              | 0 (0.0)       |         |
| Never                                        | 1 (2.0)              | 0 (0.0)       |         |
| Relationship changed during the pandemic     |                      |               | 0.98    |
| No                                           | 41 (80.4)            | 16 (84.2)     |         |
| Yes                                          | 10 (19.6)            | 3 (15.8)      |         |
| PHQ-4 Anxiety Score (mean (SD))              | 2.53 (1.75)          | 3.74 (1.66)   | 0.01    |
| PHQ-4 Depression Score (mean (SD))           | 1.43 (1.46)          | 2.74 (1.37)   | 0.001   |

Differences in categorical variables assessed by the $χ^2$ test or Fisher’s exact test as appropriate. Normally distributed continuous variables were analyzed by Student’s t-test, while others were analyzed using the Wilcoxon rank-sum test. The significance level was 0.05.
dysfunction may wish to screen for the presence of pandemic-related stressors. In light of recent evidence that demonstrates sexual activity can have a protective effect on the development quarantine-related anxiety and mood disorders, optimization of patients’ sexual health and optimization of patients’ mental health are reciprocal and synergistic goals.32

This study should be considered in the context of its limitations. Though this is the first study to assess sexual function and frequency among American women during the COVID-19 pandemic, the United States is a heterogenous nation, and the response to it has varied geographically. As such, an analysis of the entire country may lose region-specific aspects of impacts on female sexual function. Second, we leveraged a convenience sample of women surveyed immediately prior to the pandemic who made a purchase at a cannabis dispensary which may limit generalizability. Additionally, the average overall FSFI score found in our sample is higher than the average FSFI score reported in other studies, which may additionally limit generalizability. Finally, an established limitation of the FSFI is its inability to quantify the sexual function of sexually inactive women.17 In order to address this, we only examined women who were sexually active, and thus our results may not be applicable to sexually inactive women.

Nevertheless, the present study is the first to examine female sexual function and frequency during the COVID-19 pandemic in the United States. We report an increase in female sexual dysfunction and no change in frequency of intercourse. Additionally, the development of risk for sexual dysfunction was associated with symptoms of depression and anxiety during the pandemic. Therefore, further investigation of strategies to improve both female sexual and mental health during a pandemic (e.g. in person or virtual visits with clinicians, therapists, and psychologists) may be warranted.

Corresponding Author: Hriday P. Bhambhvani, BS, Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Palo Alto, CA 94305, USA, Tel: (650) 723-3391, Fax: (650) 498-5346.; E-mail: hriday@stanford.edu

Conflicts of Interest: The authors report no conflicts of interest.

Funding: None.

STATEMENT OF AUTHORSHIP

Conceptualization, All Authors; Data curation, H.B., T.C., and A.K.; Formal Analysis, H.B. and T.C.; Investigation, All Authors; Methodology, All Authors; Writing – Original Draft, H.B. and T.C.; Writing – Review & Editing, All Authors; Supervision, G.W., E.E., and M.E.

REFERENCES

1. Silva PCL, Batista PVC, Lima HS, et al. COVID-ABS: An agent-based model of COVID-19 epidemic to simulate health and economic effects of social distancing interventions. Chaos Solitons Fractals 2020;139:110088.
2. Bhambhvani HP, Rodrigues AJ, Yu JS, et al. Hospital volumes of 5 medical emergencies in the covid-19 pandemic in 2 us medical centers. JAMA Intern Med 2021;181:272–274.
3. Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord 2020;277:55–64.
4. Achdut N, Refaeli T. Unemployment and psychological distress among young people during the covid-19 pandemic: psychological resources and risk factors. Int J Environ Res Public Health 2020;17:7163.
5. Del Boca D, Oggero N, Profeta P, et al. Women’s and men’s work, housework and childcare, before and during COVID-19. Rev Econ Househ 2020;18:1001–1017.
6. Landivar LC, Ruppanner L, Scarborough WJ, et al. Early signs indicate that COVID-19 is exacerbating gender inequality in the labor force. Socius 2020;6 2378023120947997Published 2020 Aug 3. doi: 10.1177/2378023120947997.
7. World Health Organisation. Defining Sexual Health 2020. Available at: https://www.who.int/reproductivehealth/topics/sexual_health/sh_definitions/en/. Accessed May 22, 2021.
8. Pennanen-Iire C, Prereira-Lorenço M, Padoa A, et al. Sexual health implications of covid-19 pandemic. Sex Med Rev 2021;9:3–14.
9. Pascoal PM, Carvalho J, Raposo CF, et al. The impact of COVID-19 on sexual health: A preliminary framework based on a qualitative study with clinical sexologists. Sex Med 2020;9:100299. doi: 10.1016/j.jsxm.2020.100299.
10. Schiavi MC, Spina V, Zullo MA, et al. Love in the time of covid-19: Sexual function and quality of life analysis during the social distancing measures in a group of Italian reproductive-age women. J Sex Med 2020;17:1407–1413.
11. Lehmiller Justin J, Garcia Justin R, Gesselman Amanda N, et al. Less sex, but more sexual diversity: Changes in sexual behavior during the COVID-19 coronavirus pandemic. Leisure Sciences 2020. doi: 10.1080/01490400.2020.1774016.
12. Jacob L, Smith L, Butler L, et al. Challenges in the practice of sexual medicine in the time of COVID-19 in the United Kingdom. J Sex Med 2020;17:1229–1236.
13. Li W, Li G, Xin C, et al. Challenges in the practice of sexual medicine in the time of COVID-19 in China. J Sex Med 2020;17:1225–1228.
14. Kasman AM, Bhambhvani HP, Wilson-King G, et al. Assessment of the association of cannabis on female sexual function with the female sexual function index. Sex Med 2020;8:699–708.
15. Bhambhvani HP, Kasman AM, Wilson-King G, et al. A survey exploring the relationship between cannabis use characteristics and sexual function in men. Sex Med 2020;8:436–445.
16. Chen T, Bhambhvani HP, Kasman AM, Eisenberg ML. The association of the COVID-19 pandemic on male sexual function in the United States: A survey study of male cannabis users. Sex Med 2021;9:100340.
17. Hevesi K, Mészáros V, Kövi Z, et al. Different characteristics of the female sexual function index in a sample of sexually active and inactive women. J Sex Med 2017;14:1133–1141.
18. Wieg M, Meston C, Rosen R. The female sexual function index (FSFI): Cross-validation and development of clinical cut-off scores. J Sex Marital Ther 2005;31:1–20.
19. Kroenke K, Spitzer RL, Williams JB, et al. An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics 2009;50:613–621.
20. Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: Validation and standardization of the patient health questionnaire-4 (PHQ-4) in the general population. J Affect Disord 2010;122:86–95.
21. Whitley E, Ball J. Statistics review 6: Nonparametric methods. Crit Care 2002;6:509–513.
22. Benke C, Autenrieth LK, Asselmann E, et al. Lockdown, quarantine measures, and social distancing: Associations with depression, anxiety and distress at the beginning of the COVID-19 pandemic among adults from Germany. Psychiatry Res 2020;293:113462. doi: 10.1016/j.psychres.2020.113462.
23. Ettman CK, Abdalla SM, Cohen GH, et al. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open 2020;3:e2019686. Published 2020 Sep 1. doi: 10.1001/jama.net open.2020.19686.
24. Schiavi MC, Spina V, Zullo MA, et al. Love in the time of COVID-19: Sexual function and quality of life analysis during the social distancing measures in a group of Italian reproductive-age women. J Sex Med 2020;17:1407–1413.
25. Fuchs A, Matonog A, Pilarska J, et al. The impact of COVID-19 on female sexual health. Int J Environ Res Public Health 2020;17:E7152.
26. Omar SS, Dawood W, Eid N, et al. Psychological and sexual health during the COVID-19 pandemic in Egypt: Are women suffering more. Sex Med. https://doi.org/10.1016/j.esxm.2020.100295.
27. Cito G, Micelli E, Cocci A, et al. The impact of the COVID-19 quarantine on sexual life in Italy. Urology. [published online: September 01, 2020]. https://doi.org/10.1016/j.urology.2020.06.101.
28. Arafat SMY, Alradie-Mohamed A, Kar SK, et al. Does COVID-19 pandemic affect sexual behaviour? A cross-sectional, cross-national online survey. Psychiatry Res 2020;289:113050. doi: 10.1016/j.psychres.2020.113050.
29. Stephenson KR, Toorabally N, Lyons L, et al. Further validation of the female sexual function index: specificity and associations with clinical interview data. J Sex Marital Ther 2016;42:448–461.
30. Sreeekshmy K, Velayudhan R, Kuriakose D, et al. Sexual dysfunction in females with depression: A cross-sectional study. Trends Psychiatry Psychother 2017;39:106–109.
31. Clayton AH, Durgam S, Tang X, et al. Characterizing sexual function in patients with generalized anxiety disorder: A pooled analysis of three vilazodone studies. Neuropsychiatr Dis Treat 2016;12:1467–1476. Published 2016 Jun 21. doi: 10.2147/NDT.S103408.
32. Mollaioli D, Sansone A, Ciocca G, et al. Benefits of sexual activity on psychological, relational, and sexual health during the COVID-19 breakout. J Sex Med 2021;18:35–49.

SUPPLEMENTARY MATERIALS

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.esxm.2021.100355.